抗抑郁药反应的个体差异:安慰剂对照随机临床试验的荟萃分析
基线严重度未调节变异性;SSRI及其他抗抑郁药变异性低于去甲肾上腺素能药物,且发表年份越近变异性越低。结论支持抗抑郁药反应存在系统性个体差异,为个体化治疗提供依据。
要点
- 抗抑郁药反应变异性显著高于安慰剂,提示存在系统性个体差异。
- 基线抑郁严重度不影响抗抑郁药反应变异性。
- SSRI及其他抗抑郁药变异性低于去甲肾上腺素能药物。
核心结论
- 抗抑郁药治疗重性抑郁障碍的症状反应变异性显著高于安慰剂,提示个体差异可能系统性存在。
- 该研究为识别调节因素和个体化抗抑郁药治疗提供了实证支持。
研究设计与样本
- 研究基于近期一项成人重性抑郁障碍急性治疗许可抗抑郁药的网络荟萃分析数据。
- 仅纳入双盲、随机、安慰剂对照试验,且研究终点数据可获取。
- 提取基线及终点均值、标准差、各组人数、抗抑郁药类别和发表年份,于2019年8月14日至11月18日分析。
主要发现
- 抗抑郁药反应变异性显著高于安慰剂,变异系数比为1.14(95%CI 1.11-1.17,P<.001)。
- 基线抑郁严重度未调节抗抑郁药反应变异性。
- SSRI反应变异性低于去甲肾上腺素能药物,变异系数比为0.88(95%CI 0.80-0.97,P=.01)。
- 其他抗抑郁药反应变异性也低于去甲肾上腺素能药物,变异系数比为0.87(95%CI 0.79-0.97,P=.001)。
- 发表年份越近,变异性倾向于越低,每新一年变异系数变化值为0.005(95%CI 0.002-0.008,P=.003)。
关键数值与推荐
- SSRI与去甲肾上腺素能药物变异系数比0.88(95%CI 0.80-0.97,P=.01)。
- 其他抗抑郁药与去甲肾上腺素能药物变异系数比0.87(95%CI 0.79-0.97,P=.001)。
- 发表年份每新一年变异系数变化值0.005(95%CI 0.002-0.008,P=.003)。
临床怎么用
- 临床应认识到抗抑郁药反应存在超出安慰剂效应的系统性个体差异,关注患者个体特征。
- 选择抗抑郁药时可考虑药物类别间反应变异性的差异,如SSRI变异性低于去甲肾上腺素能药物。
- 基线抑郁严重度可能不预测反应变异性,个体化评估需综合其他因素。
局限性
- 分析仅限双盲随机安慰剂对照试验且终点数据可获取者,可能引入选择偏倚。
- 研究未涉及原文未报告的其它潜在调节因素或机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressants are commonly used worldwide to treat major depressive disorder. Symptomatic response to antidepressants can vary depending on differences between individuals; however, this variability may reflect nonspecific or random factors. OBJECTIVES: To investigate the assumption of systematic variability in symptomatic response to antidepressants and to assess whether this variability is associated with severity of major depressive disorder, antidepressant class, or year of study publication. DATA SOURCES: Data used were from a recent network meta-analysis of acute treatment with licensed antidepressants in adults with major depressive disorder. The following databases were searched from inception to January 8, 2016: the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, and PsycINFO. Additional sources were international trial registries, drug approval agency websites, and key scientific journals. STUDY SELECTION: Analysis was restricted to double-blind, randomized placebo-controlled trials with available data at the study's end point. DATA EXTRACTION AND SYNTHESIS: Baseline and end point means, SDs, number of participants in each group, antidepressant class, and publication year were extracted. The data were analyzed between August 14 and November 18, 2019. MAIN OUTCOMES AND MEASURES: With the use of validated methods, coefficients of variation were derived for antidepressants and placebo, and their ratios were calculated to compare outcome variability between antidepressant and placebo. Ratios were entered into a random-effects model, with the expectation that response to antidepressants would be more variable than response to placebo. Analysis was repeated after stratifying by baseline severity of depression, antidepressant class (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vilazodone; serotonin and norepinephrine reuptake inhibitors: desvenlafaxine and venlafaxine; norepinephrine-dopamine reuptake inhibitor: bupropion; noradrenergic agents: amitriptyline and reboxetine; and other antidepressants: agomelatine, mirtazapine, and trazodone), and publication year. RESULTS: In the 87 eligible randomized placebo-controlled trials (17 540 unique participants), there was significantly more variability in response to antidepressants than to placebo (coefficients of variation ratio, 1.14; 95% CI, 1.11-1.17; P < .001). Baseline severity of depression did not moderate variability in response to antidepressants. Variability in response to selective serotonin reuptake inhibitors was lower than variability in response to noradrenergic agents (coefficients of variation ratio, 0.88; 95% CI, 0.80-0.97; P = .01), as was the variability in response to other antidepressants compared with noradrenergic agents (coefficients of variation ratio, 0.87; 95% CI, 0.79-0.97; P = .001). Variability also tended to be lower in studies that were published more recently, with coefficients of variation changing by a value of 0.005 (95% CI, 0.002-0.008; P = .003) for every year a study is more recent. CONCLUSIONS AND RELEVANCE: Individual differences may be systematically associated with responses to antidepressants in major depressive disorder beyond placebo effects or statistical factors. This study provides empirical support for identifying moderators and personalizing antidepressant treatment.
引用
- Maslej MM, Furukawa TA, Cipriani A, et al. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. JAMA Psychiatry. 2020. PMID: 32074273. doi:10.1001/jamapsychiatry.2019.4815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。